https://mindmedicinelaw.com/briefing/psychedelic-pharmacology-s-role-in-neuropsychiatric-drug-development-20260801-28421The Psychedelic Journalen2026-08-02T15:05:04.947799+00:00Psychedelic Pharmacology's Role in Neuropsychiatric Drug Developmentpsychedelic pharmacology, neuropsychiatric drug development, mental health disorders, clinical trials, psychedelic research, psilocybin, MDMA, neuroplasticity, psychiatric care, safety evaluationshttps://mindmedicinelaw.com/briefing/psychedelic-informed-therapeutics-for-depression-a-new-frontier-20260731-28181The Psychedelic Journalen2026-08-01T22:07:09.855319+00:00Psychedelic-informed Therapeutics for Depression: A New Frontierpsychedelic therapeutics, depression treatment, synaptic plasticity, inflammation-plasticity coupling, psychoplastogens, ketamine, serotonergic psychedelics, rapid-acting antidepressants, biomarker-guided treatment, neuroinflammationhttps://mindmedicinelaw.com/briefing/experience-trajectory-framework-enhancing-psychedelic-safety-20260731-28204The Psychedelic Journalen2026-08-01T22:06:46.122997+00:00Experience-Trajectory Framework: Enhancing Psychedelic Safetypsychedelic therapy, experience-trajectory framework, substance-specific risk, safety protocols, baseline risk state, clinical trials, neuroscience, public health, preparation standards, aftercarehttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-post-cesarean-sleep-disorders-20260731-28191The Psychedelic Journalen2026-08-01T22:06:26.895293+00:00Esketamine's Role in Reducing Post-Cesarean Sleep Disordersesketamine, postoperative sleep disorders, cesarean section, obstetric anesthesia, postpartum depression, analgesic efficacy, clinical guidelines, anesthesia management, NMDA receptor antagonist, maternal-neonatal complicationshttps://mindmedicinelaw.com/briefing/medicare-fy-2027-update-implications-for-psychedelic-therapies-20260731-27600The Psychedelic Journalen2026-07-31T22:05:55.979315+00:00Medicare FY 2027 Update: Implications for Psychedelic Therapiesmedicare update, inpatient psychiatric facilities, psychedelic therapies, payment rates, quality measures, psychiatric care, healthcare policy, psychedelic integration, financial incentives, treatment modalitieshttps://mindmedicinelaw.com/briefing/childhood-trauma-s-impact-on-psychedelic-outcomes-explored-20260730-28148The Psychedelic Journalen2026-08-02T15:05:46.767116+00:00Childhood Trauma's Impact on Psychedelic Outcomes Exploredchildhood trauma, psychedelic outcomes, psilocybin, ayahuasca, MDMA, trauma-informed research, cultural inclusivity, psychological risks, therapeutic potential, mental healthhttps://mindmedicinelaw.com/briefing/global-study-connects-breathwork-to-enhanced-mental-well-being-20260730-28149The Psychedelic Journalen2026-08-02T15:05:37.038665+00:00Global Study Connects Breathwork to Enhanced Mental Well-beinghigh ventilation breathwork, experiential avoidance, altered states of consciousness, mental well-being, therapeutic practices, cross-sectional study, emotional breakthroughs, mental health interventionshttps://mindmedicinelaw.com/briefing/photoswitchable-orexin-antagonist-a-new-tool-for-brain-studies-20260730-28182The Psychedelic Journalen2026-08-02T15:05:29.056938+00:00Photoswitchable Orexin Antagonist: A New Tool for Brain Studiesorexin receptor, photoswitchable antagonist, psychiatric disorders, optical control, brain signaling, neuroscience research, photorexant, in vitro studies, mouse brain studies, psychedelic researchhttps://mindmedicinelaw.com/briefing/psychological-distress-and-cancer-immunotherapy-response-20260730-28183The Psychedelic Journalen2026-08-02T15:05:20.911441+00:00Psychological Distress and Cancer Immunotherapy Responsepsychological distress, cancer immunotherapy, immune response, biomarkers, psycho-neuro-immune interactions, clinical trialshttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-consciousness-new-study-insights-20260730-28208The Psychedelic Journalen2026-08-02T15:05:13.863192+00:00DMT's Impact on Consciousness: New Study InsightsDMT, consciousness, pharmacodynamics, brain dynamics, psychedelic research, therapeutic applications, alpha-band activity, functional connectivity, neuroscience, clinical trialshttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-consciousness-new-study-insights-20260730-28206The Psychedelic Journalen2026-08-01T22:06:53.787131+00:00DMT's Impact on Consciousness: New Study InsightsDMT, consciousness, brain connectivity, psychedelic research, pharmacodynamics, neuroscience, clinical trials, public health, serotonergic psychedelics, perception reorganizationhttps://mindmedicinelaw.com/briefing/mb-pat-in-canada-a-new-model-for-cancer-demoralization-20260730-28184The Psychedelic Journalen2026-08-01T22:06:36.497411+00:00MB-PAT in Canada: A New Model for Cancer Demoralizationmindfulness-based therapy, psilocybin-assisted therapy, cancer demoralization, Canadian oncology, group therapy model, psychedelic researchhttps://mindmedicinelaw.com/briefing/ketamine-guidelines-for-chronic-pain-a-scoping-review-20260730-27744The Psychedelic Journalen2026-07-31T22:06:13.897782+00:00Ketamine Guidelines for Chronic Pain: A Scoping Reviewketamine guidelines, chronic pain management, non-cancer pain, clinical protocols, NMDA receptor antagonist, patient safety, standardized treatment, pharmacological action, policy implications, research directionshttps://mindmedicinelaw.com/briefing/esketamine-nasal-spray-for-ect-refractory-bipolar-depression-20260730-27847The Psychedelic Journalen2026-07-31T22:06:04.215183+00:00Esketamine Nasal Spray for ECT-Refractory Bipolar Depressionesketamine nasal spray, ECT-refractory depression, bipolar depression treatment, treatment-resistant mood disorders, NMDA receptor antagonist, psychiatric researchhttps://mindmedicinelaw.com/briefing/esketamine-s-potential-in-cancer-related-depression-a-review-20260730-27805The Psychedelic Journalen2026-07-31T22:05:39.885026+00:00Esketamine's Potential in Cancer-Related Depression: A Reviewesketamine, cancer-related depression, rapid-acting antidepressant, NMDA receptor, BDNF, oncology care, synaptic plasticity, clinical trials, safety and efficacyhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-veterans-with-ptsd-clinical-trial-insights-20260730-27804The Psychedelic Journalen2026-07-31T22:05:31.974635+00:00Psilocybin Therapy for Veterans with PTSD: Clinical Trial Insightspsilocybin-assisted therapy, veterans, PTSD, clinical trial, treatment-resistant, mental health, psychedelic research, safety and efficacy, therapy integration, U.S. militaryhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-in-jamaica-case-studies-highlight-potential-20260729-27634The Psychedelic Journalen2026-08-01T15:05:23.356262+00:00Psilocybin Therapy in Jamaica: Case Studies Highlight Potentialpsilocybin therapy, Jamaican case studies, psychedelic research, mental health, long-COVID, clinical trials, De La Haye Psilocybin Treatment Protocol, psychotherapy, MEQ-30, somatic symptomshttps://mindmedicinelaw.com/briefing/neurobiology-of-early-intervention-in-youth-mental-health-20260729-27654The Psychedelic Journalen2026-08-01T15:05:16.591809+00:00Neurobiology of Early Intervention in Youth Mental Healthyouth mental health, early intervention, critical periods, preventive psychiatry, neurobiology, psychedelic interventions, developmental neuroscience, mental disorders, biomarkers, systems biologyhttps://mindmedicinelaw.com/briefing/orexin-signaling-in-metabolism-and-depression-new-insights-20260729-27848The Psychedelic Journalen2026-08-01T15:05:09.204999+00:00Orexin Signaling in Metabolism and Depression: New Insightsorexin signaling, depression treatment, glucose-insulin homeostasis, seltorexant, metabolic disorders, antidepressant mechanisms, psychiatric treatment, clinical research, orexin antagonists, neurosciencehttps://mindmedicinelaw.com/briefing/fungal-metabolites-in-tauopathy-treatment-new-insights-20260728-28189The Psychedelic Journalen2026-08-01T22:07:01.511495+00:00Fungal Metabolites in Tauopathy Treatment: New Insightsfungal metabolites, tauopathies, autophagy modulators, neurodegenerative diseases, computational drug discovery, psychedelic compoundshttps://mindmedicinelaw.com/briefing/adjunctive-pharmacotherapy-for-mdd-with-anxiety-clinical-gaps-20260728-27679The Psychedelic Journalen2026-08-01T15:05:53.584134+00:00Adjunctive Pharmacotherapy for MDD with Anxiety: Clinical Gapsmajor depressive disorder, MDD with anxiety, adjunctive pharmacotherapy, clinical trials, ketamine, monoamine system, treatment gaps, anxiety-specific endpointshttps://mindmedicinelaw.com/briefing/targeting-metabolic-pathways-in-ms-a-new-therapeutic-frontier-20260728-27689The Psychedelic Journalen2026-08-01T15:05:42.490725+00:00Targeting Metabolic Pathways in MS: A New Therapeutic Frontiermultiple sclerosis, metabolic pathways, neuroinflammation, remyelination, immunometabolic reprogramming, clinical trials, biomarkers, therapeutic targets, autoimmune disorders, metabolic reprogramminghttps://mindmedicinelaw.com/briefing/ontological-tourism-in-psychedelic-science-balancing-experience-and-explanation-20260728-27655The Psychedelic Journalen2026-08-01T15:05:32.954234+00:00Ontological Tourism in Psychedelic Science: Balancing Experience and Explanationontological tourism, psychedelic research, phenomenological data, scientific integrity, consciousness science, clinical ethics, subjective experiences, mechanistic explanations, epistemological tension, psychedelic phenomenologyhttps://mindmedicinelaw.com/briefing/psilocybin-microdosing-alters-epigenetics-in-rat-brain-20260728-27670The Psychedelic Journalen2026-07-31T22:05:47.760674+00:00Psilocybin Microdosing Alters Epigenetics in Rat Brainpsilocybin microdosing, epigenetic changes, rat brain, neuroplasticity, mood disorders, anxiety disorders, serotonin receptor, histone acetylation, clinical research, psychedelic therapy